Advancements in Clinical Trials in Oncology: Design, Enrichment, Safety, Operations, Patient Centricity, and Endpoints

Dear Colleagues, 

I am pleased to announce a Special Issue in Current Oncology, titled "Advancements in Clinical Trials in Oncology: Design, Enrichment, Safety, Operations, Patient Centricity, and Endpoints", for which I am honored to serve as the Guest Editor. This issue seeks to explore the latest developments in early-phase and late-phase trial design, adaptive designs for targeted therapies, immunotherapies, and cell and gene therapy trials, and the integration of patient-centric elements in oncology clinical trials.

The landscape of oncology clinical trials has undergone remarkable transformations, witnessing rapid developments and breakthrough therapies receiving advanced approvals. As such, it is essential to highlight the novel approaches in trial design, ensuring safety, efficacy, and meaningful outcomes in this dynamic environment.

This Special Issue will delve into cutting-edge methodologies for early-phase trial design, focusing on adaptive designs that empower flexibility and efficiency while maintaining robust statistical rigor, as well as strategies to ensure the safety of trial patients. Emphasizing targeted therapies and biologics, we aim to discuss how adaptive designs can address the unique challenges posed by these groundbreaking therapeutic modalities.

Furthermore, we acknowledge the importance of patient centricity in clinical trials. We will explore innovative strategies to incorporate patient perspectives and preferences into trial design, fostering better communication, adherence, and overall trial experience for participants.

Finally, we also encourage submissions focusing on the critical aspects of biomarker enrichment and biomarker-based endpoints, as they play a pivotal role in tailoring oncology clinical trials and refining patient stratification strategies, ultimately enhancing the precision and effectiveness of novel therapies in the era of personalized medicine.

Together, let us explore the forefront of trial design, safety, operations, patient centricity, and statistics to advance cancer care, improve patient outcomes, and foster interdisciplinary discussions that will contribute to shaping the future of clinical trials in oncology.

Dr. Brandon Michael Henry
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• oncology clinical trials
• drug safety
• endpoints
• biomarkers
• study design
• methodology
• biologics
• targeted therapies